FutuRx
Stage
Corporate Minority | AliveTotal Raised
$30MLast Raised
$30M | 6 yrs agoAbout FutuRx
FutuRx is the Israeli biotechnology incubator that was established in January 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation, JJDC, and Takeda Pharmaceutical Company, through its venture group Takeda Ventures.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Research containing FutuRx
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned FutuRx in 1 CB Insights research brief, most recently on Apr 19, 2021.
Latest FutuRx News
Jan 20, 2022
Cancer therapy co ImmPACT Bio raises $111m Immpact was formed from a merger between US company Kalthera and a company founded in Israel's FutuRX biotech incubator. Israeli-American company ImmPACT Bio , which is developing the next generation of cancer cell therapies, has announced the completion of a $111 million financing round. ImmPACT Bio was formed a merger between Israeli company Immpact, which was raised in the FutuRX biotechnology incubator, and US company Kalthera, which was founded in the sector in California. RELATED ARTICLES FutuRX, headed by Erez Chimovits, is part of the Israel Innovation Authority's network of technological incubators, which is dedicated to drug development. The incubator franchisee is a consortium of the OrbiMed venture capital fund, Japanese pharmaceutical giant Takeda and Johnson & Johnson. OrbiMed participated in today's financing round, which was led by venBio Partners along with co-leads Foresite Capital and Decheng Capital along with Surveyor Capital and existing investors Novartis Venture Fund, RM Global Partners (RMGP), and Bukwang Pharmaceutical. Chimovits has until now been chairman. ImmPACT's logic-gate based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to address antigen escape, 'on-target - off-tumor' toxicities, and the immunosuppressive tumor microenvironment. ImmPACT Bio has appointed Sumant Ramachandra as president and CEO. He said, "The US company brings with it two products, one of which is already in human clinic trials and one in advanced clinical trials." Both products are in the field of Tandem CAR, He added, "But the Israeli product is even more interesting. It is based on research by Prof. Gidi Gross from the Migal Institute. Gross was one of the researchers who wrote the article on which Kite pharma was based, and which is considered one of the pioneers in the CAR sector, and was which was acquired by Gilead for $11.9 billion." The company has two research centers in California and Israel and with the money raised it will build new research laboratories and a small production plant for therapies for clinical trials. The company has 23 employees and aims to increase the number to 65 by the end of the year. Published by Globes, Israel business news - en.globes.co.il - on January 20, 2022. © Copyright of Globes Publisher Itonut (1983) Ltd., 2022.
FutuRx Frequently Asked Questions (FAQ)
Where is FutuRx's headquarters?
FutuRx's headquarters is located at P.O.Box 4044, Ness Ziona.
What is FutuRx's latest funding round?
FutuRx's latest funding round is Corporate Minority.
How much did FutuRx raise?
FutuRx raised a total of $30M.
Who are the investors of FutuRx?
Investors of FutuRx include RM Global Partners.
Who are FutuRx's competitors?
Competitors of FutuRx include TLV Partners and 3 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare FutuRx to Competitors
TLV Partners is a Venture Capital firm that focuses on investing in A-round startups. It connects entrepreneurs with the resources and community they need, the firm aims to make a lasting impact. The company is based in Tel Aviv, Israel.
Hasso Plattner Ventures, founded in July 2005, is a venture capital firm investing in software, web service providers, and cleantech. They focus on investing in Israel and Europe, primarily targeting Germany, Austria, and Switzerland. The firm's minimum investment is 500,000 Euros and they will invest up to 10 million Euros over the life of a portfolio company. They invest primarily in equity. The firm also aims to provide portfolio companies unique value via conferences and other events the firm plans to facilitate exchange of experiences, information, and contacts. Amongst these events are: - Founders club - a regular meeting of the portfolio company executives and industry experts - DesignIT - an annual forum on design and its implications for IT and entrepreneurship - Open Source Business Forum - a platform for entrepreneurs to present their ideas in the Open Source segment to renowned managers and venture capitalists - Network Centric Services Conference - a platform for entrepreneurs with a focus on network-centric services, media provisioning, and seamless services. SAP co-founder Prof. Dr. h.c. Hasso Plattner provided the lion's share of this investment capital, along with InvestitionsBank of Brandenburg and CMEA Ventures.
i3 Equity helps entrepreneurs through seed investments and mentorship. It is based in Tel Aviv, Israel.
Johnson & Johnson Innovation is the venture capital subsidiary of Johnson & Johnson. JJI is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, Johnson & Johnson Innovation determines the success of an investment's performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.
Shonan Health Innovation Park (Shonan iPark) operates a pharma-led innovative ecosystem comprised of researchers, industry experts, venture startups, government, and academia who collaborate and co-create in order to accelerate research with the aim of transformation. It prefers to invest in companies operating in the life sciences, biotech, and pharmaceutical sectors. It was founded in 2018 and is based in Fujisawa, Japan.
SwitchPitch is a B2B Saas platform used by enterprise teams to partner with startups. Enterprises add emerging technology needs and SwitchPitch's engine leverages Al/ ML to align amazing startups.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
